← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 29.9% to $129.4M, while Net income increased 103.3% to $17.4M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $129.4MOK
- Profitability — Net income $17.4MOK
- Cash generation — Free cash flow N/ANote
- Accounting — Formula-grey distress score · manipulation flag raised · earnings quality safeWatch
- Insiders — 1 buys; 0 sells in 365 daysOK
- Capital — share repurchases were $251.0KNote
Business
Niagen Bioscience, Inc.: our business, business strategy, products and services we may offer in the future, the outcome and impact of litigation, the timing and results of future regulatory filings, the timing and results of future clinical trials, our ability to collect from major customers, sales and marketing strategy and capital outlook.
Where the revenue comes from
Fiscal 2025, as Niagen Bioscience, Inc. reports it. History and quarterly detail are in the app.
- Consumer Products$97.7M
- Ingredients$28.7M
- Analytical Reference Standards and Services$3.1M
Leadership changes
From Niagen Bioscience, Inc.'s own filings, the day they're filed.
- Ozan Pamir · Chief Financial Officer · appointmenteff. 2024-10-21
- James Lee · Chief Financial Officer · appointmenteff. 2024-10-21
- Brianna Gerber · Chief Financial Officer · departureeff. 2024-07-13
Latest filings
- 8-K · Company announcement2026-08-04
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-06-29
- 10-Q · Quarterly report2026-05-06
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Niagen Bioscience, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.